Mirum Pharmaceuticals is a biopharmaceutical company focused on rare liver diseases and related cholestatic conditions. Its marketed therapies include treatments such as Livmarli (maralixibat) for cholestatic pruritus in genetic liver disorders like Alagille syndrome. The company targets small patient populations with high unmet need through specialty hepatology products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 127.8 | — | -5.9 | — |
| Q3 2025 | 133 | — | 2.9 | — |
| Q4 2025 | 148.9 | — | -5.7 | — |
| Q1 2026 | 159.9 | — | -790.1 | — |
| Q2 2026 | 176.2 | 37.9% | -67.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Grifols, S.A. (GRFS), Riot Platforms, Inc. (RIOT), Cogent Biosciences, Inc. (COGT), Remitly Global, Inc. (RELY), Sotera Health Company (SHC), Calumet, Inc. (CLMT)